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Alice Gottlieb has received consulting fees from Janssen Inc.; Celgene Corp., The objective of this work was to use multiple methodologies to review composite measures and potential treatment targets in PsA establishing recommendations and developing a research agenda for future work. This paper reports the output of a consensus meeting, with discussions focusing on the systematic literature review data and pre and post meeting surveys of patients and physicians held in 2017.
Methods
Prior to the consensus meeting, two surveys were conducted. One survey was sent to health care The afternoon session focused on treating to target and potential targets available in PsA. These included cut points of these composite measures where available but focussed specifically on DAPSA remission/low disease activity (7), the minimal disease activity (MDA) criteria(8) and more stringent very low disease activity (VLDA)(9) as these two measures had accumulated the most validation data. The domains included in these composite measures are shown in Table 1 .
For both sessions, after presentation of the key data for the outcome measures, breakout groups with representatives from rheumatology, dermatology and PRPs were established to discuss the pros and cons for each measure. These groups then reported back to the complete attendee group.
There was then discussion and debate on the different measures with voting on recommendations.
Results

Composite disease activity measures
Physician survey A total of 128 health care professionals responded, the majority (82%)
rheumatologists. The domains of disease most commonly assessed in clinical practice were joints (97%), dactylitic digits (88%), entheses (87%), pain (86%), CRP/ESR (86%) and skin (84%). When asking specifically about composite measures, 45% of HCPs reported that they regularly use a composite measure in their practice, most commonly the minimal disease activity (MDA) or the routine assessment of patient index data (RAPID3). The majority of respondents thought that a single composite measure was more clinically useful than individual assessment of each domain, and they felt that such composites should include measures of arthritis, enthesitis, dactylitis, inflammatory markers and patient global scores. The failure to recommend inclusion of a psoriasis assessment is related to the low number of dermatology respondents. The dermatologists chose skin measures as their top items but included the same measures as the rheumatologists (highlighted above) as their subsequent choices.
Patient survey A total of 139 patients responded. Most reported that they see their physician every 6 months for assessment, and the majority (84%) reported that their physician assessed only painful or problematic joints rather than a formal joint count. Less than a quarter of patients are asked to complete any questionnaires at or prior to their appointment although 91% would be willing to do so if asked. The most important domains of disease highlighted by the patients were pain (46%), joints (36%) and physical function.
Discussion on measures
Breakout groups were then convened to discuss the following measures: PASDAS, GRACE, CPDAI, DAPSA and the RAPID3 and 3-VAS scores. The pros and cons of these measures highlighted by the breakout groups and subsequent discussions are shown in (10) . These data show that the inclusion of skin disease in a composite psoriatic disease measure identifies a treatment effect in psoriatic disease as a whole despite no differential effect on MSK activity. Some felt that composites covering multiple domains were optimal to quantify the overall burden of disease activity for each patient but clarified that these should then be reported with their individual components to assess each domain as well as total scores.
There was much discussion concerning the outcome measures in general but in particular about whether it is appropriate to include measures of physical function or HRQoL in a disease activity index. These items may be considered measures of impact, influenced by cumulative damage as well as activity. Whilst not ideal to have different measures, the varying feasibility for daily clinical practice and clinical trials was also discussed.
The GRACE was felt to be a valuable composite but inclusion of the psoriasis area and severity index (PASI) was felt to be impractical for clinical usage. Ideally the measure of skin disease should be feasible for non-dermatologists. Adaptation of the GRACE measure with a simpler skin tool to replace the PASI may help but this would require further validation.
RAPID3 is a commonly used generic measure of disease activity, particularly used in practice in the US. Whilst the SLR showed preliminary validation in PsA, it was developed for RA and is focused on peripheral joint disease. A modification with a psoriasis VAS (RAPID3Ps) has also been tested which may be more helpful in patients with significant skin disease.
The 3VAS score was initially developed from the GRACE project but has not been widely published.
It consists of an average of 3 VAS: patient skin, patient global and physician global. This is quick and feasible but does not include any objective inflammation measures. Whilst this is similar in 'APID examination) could be a benefit. However there is little validation of this measure to date. For both RAPID3 and 3VAS there was discussion about the potentially significant impact of comorbid fibromyalgia which may disproportionately affect these composites.
DAPSA is specifically a measure of peripheral arthritis without any inclusion of other domains.
Several attendees commented that this was a good measure of peripheral arthritis, but separate assessment of skin disease and potentially other domains should be mandated alongside DAPSA to ensure a full assessment of PsA disease activity.
Following the discussion, all attendees (rheumatologists, dermatologists and patient research partners) voted on the optimal composite scores for RCTs and clinical practice. Each participant had up to five votes for the best measure for use in trials and up to five votes for the best measure in clinical practice. These could be assigned to one measure, or distributed across them. The outcome of the vote was spread across measures, with no single measure receiving a strong vote in favour for use in both settings (Figure 1 ). For use in RCTs, PASDAS received the highest number of votes (n=40) followed by GRACE (n=28) and CPDAI (n=25) whilst for clinical practice, 3VAS received the highest number of votes (n=45) followed by DAPSA (n=26) and CPDAI (n=23). A number of items were identified for the research agenda.
At the end of this session, it was agreed that any measure disease is fully assessed and patient-reported outcomes are included in the evaluation. It is important to look at how existing composite measures could be modified for future use.
Potential treatment targets
Physician survey The majority of HCPs (57%) believe that remission should be the optimal target of treatment with an alternative of low or minimal disease activity. The most important factors that would influence HCPs when setting the treatment target include co-morbidities (81%), disease activity (79%) and patient goals (65%). At present, 56% of HCPs report that they do treat-to-target in clinical practice and the three most popular targets utilised are MDA (32%), followed by DAS28 low disease activity (LDA) (10%) and DAS28 remission (9.5%). Assessment of joints, health related quality of life, and skin and nails, were most frequently mentioned as domains to include for a treat to target approach.
Patient survey Again the majority of patients (56%) agree that remission or alternatively MDA/LDA should be the treatment target and most patients (45%) defined of disease or symptoms. However the majority (61%) report that they have not discussed personal goals for managing their PsA with their rheumatologist and nearly 1 in 5 patients want their rheumatologist to listen to their concerns more.
Discussion on targets
The first discussion was the conceptual target of treatment. The only treat to target study in PsA used MDA as the target (11), a measure of low disease activity rather than remission. Despite this, the treatment arm had a higher rate of adverse events so it was discussed that the risks and benefits should be evaluated in each individual patient case. In line with previous EULAR treatment recommendations (12) and the 2017 treat to target taskforce recommendations (13) , the group unanimously agreed that remission should be the treatment target, but in certain circumstances, LDA/MDA is a reasonable alternative.
Breakout groups were then convened to discuss the following targets: VLDA, MDA, modifications of MDA where some items are mandated and DAPSA remission/low disease activity. The pros and cons of these measures highlighted by the breakout groups and subsequent discussions are shown in Table 3 .
Given the nature of the disease, the majority of attendees felt that for face validity, any measure of remission or low disease activity should assess multiple domains of disease, particularly peripheral arthritis and skin as these are the most prevalent domains. Whilst rheumatologists tend to prioritise joints over skin when treating their patients with PsA, skin disease is highly important and impactful to patients, with residual skin disease being associated with a poorer function and quality of life (14) .
When considering concepts such as remission the whole patient should be assessed.
DAPSA can be used both as a measure of disease activity and a target. However DAPSA is designed to measure peripheral arthritis with even the patient global VAS score asking about joint disease. In some RCTs of biologics the levels of active skin disease and enthesitis of those in DAPSA remission are similar to VLDA (15) . However in studies of patients with significant baseline skin disease and recent real life clinic datasets, research has shown that patients in DAPSA remission can have significant levels of active skin disease with associated impact on HRQoL which goes against the face validity of such a measure as defining remission of psoriatic disease (16) (17) (18) (19) . A potential solution would be to require physicians to assess multiple targets for individual measures such as peripheral arthritis and skin disease. However there is a concern that physicians may not perform all assessments and therefore active disease would be missed. Research on DAPSA also showed higher levels of residual disease activity than in VLDA/MDA possibly due to the nature of DAPSA as a summary score where one element can be high if the others are low (16) (17) (18) (19) .
MDA/VLDA is a measure of disease state, not a measure of disease activity therefore if MDA is recommended as the target, a different composite of disease activity would still be required. MDA and VLDA do not include a measure of acute phase reactants allowing calculation before blood results are known. However it is recommended that acute phase reactants should be tested in addition to the clinical criteria aiming for normalisation in a chronic inflammatory disease (13) . The design of MDA is modular with each item assessed individually but as only 5 of the 7 criteria must be met for MDA, residual disease can occur in one domain, particularly skin as only one item measures skin disease directly. This is not the case with VLDA (where all cutpoints must be met) or modifications that require the skin and/or joint items to be met. Concern was raised about the inclusion of health assessment questionnaire (HAQ) as one of the items in MDA/VLDA. This could potentially prevent patients from achieving VLDA despite adequate control of inflammatory disease activity due to accumulated damage. However in this case, the patient would achieve MDA as the alternative target.
Following on from these discussions on the use of targets in PsA, attendees first voted on the domains that should be considered in a target. The group unanimously agreed that when assessing a target of treatment, there should ideally be assessment of musculoskeletal disease, skin disease, and disease impact/HRQoL.
There was agreement that both MDA and DAPSA had advantages and disadvantages and more research should be done. However, in the absence of data, it was agreed that the rheumatology community needs guidance on what to use now to encourage a treat-to-target approach. This was observed with DAS28 in RA, which was initially not liked but is now widely accepted. Therefore a motion was proposed he group at present recommends a target of treatment as VLDA (remission), or MDA 5/7 as an alternative low/MDA This was not unanimously supported, there were 21 votes in favour, 2 against and 1 abstention.
Post meeting survey
Physician survey A total of 115 HCPs responded to the second survey, the majority (77%)
rheumatologists. Most supported the development of composites but agreed with the advantages and disadvantages listed. Overall the RAPID3 and 3VAS were felt to be quick and feasible but not comprehensive enough with no objective measures included. DAPSA was feasible but only included assessment of peripheral arthritis and was felt to be more appropriate for polyarticular disease.
GRACE, PASDAS and CPDAI were felt to be comprehensive but less feasible for routine practice. The balance between inclusion of key domains but without being time consuming was felt to be key.
Less than 10 minutes, or ideally less than 5 minutes was felt to be reasonable for clinical practice.
CPDAI was the highest ranked (6.4/10) for use in clinical practice but all scores were ranked between 4.5 and 6.5. For RCTs, CPDAI, PASDAS and GRACE were felt to be the most appropriate scoring 6.7, 6.4 and 6.6 out of 10, with the rest less popular. The vast majority (93%) supported the decision from the meeting that all measures should be studied further and data should be collected to allow comparison.
The specific issue of the inclusion of HAQ in some measures was also addressed. HRQoL. They also specifically mentioned fatigue, enthesitis and physical function as key domains.
The vast majority (90%) supported the concept of remission or alternatively LDA as a target and the recommendation for the use of VLDA/MDA (77%).
Research Agenda
Throughout the meeting, items for the research agenda were identified and noted. Whilst a significant amount of data is available for the composites following recent research, as identified by the SLR, there is still a lot to understand about these measures. Many composite measures were developed without substantial patient involvement and this should be addressed in future research.
Recent research has highlighted that concomitant fibromyalgia impacts on all disease outcome measures and this must be considered. For specific measures a variety of validation data is missing.
In particular, there has been very little analysis on the 3VAS measure and this needs a lot more validation. For some of the composite measures, additional data is particularly required on the validity of the cut points as potential targets such as those for PASDAS and CPDAI.
A number of research agenda items related to less well studied domains including axial disease, fatigue and nail disease. Whilst many measures include a patient global, there is a wide variety of the wordings used in these composites which would benefit from further analysis and standardisation. There were also a number of potential modifications that were suggested for the existing composites. For the multi-domain measures the majority of modifications were related to simplification (eg BSA or PGA x BSA substituted for PASI) or substitution of HRQoL or physical function measures. For DAPSA, there was interest in studying DAPSA alongside a skin measure, particularly when considering it as a target. Particularly for potential targets, additional data directly comparing measures, and their concordance/discordance will be valuable to understand them further.
Summary
Within the OMERACT framework for developing a core outcome measurement set for PsA (2) 
